Publications by authors named "Sydney Bringgold"
Ann Pharmacother
October 2024
Article Synopsis
- Hypoalbuminemia is prevalent in cancer patients, particularly those with advanced solid tumors, and its impact on the safety of high-protein-bound tyrosine kinase inhibitors (TKIs) is under-researched.
- A study examined 282 patients taking oral TKIs, finding that those with hypoalbuminemia had a significantly shorter median time on treatment and experienced more severe adverse events compared to those with normal albumin levels.
- The findings suggest that patients with hypoalbuminemia are at a higher risk of adverse events and require careful monitoring when undergoing TKI therapy.
